Aficamten vs HRS-1893

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Hypertrophic Cardiomyopathy

Shared mechanism: Cardiac myosin (inhibitor) · full Hypertrophic Cardiomyopathy pipeline

Aficamten · Myqorzo

Marketed by Cytokinetics and partners

Approved in Hypertrophic Cardiomyopathysmall molecule
Reliable signal

NCT05767346 · Phase 3 · completed

This randomized, triple-blind, active-controlled Phase 3 trial (n=175) compared aficamten with the beta-blocker metoprolol succinate in adults with symptomatic obstructive hypertrophic cardiomyopathy. The primary endpoint, change in peak oxygen uptake on exercise testing at 24 weeks, improved significantly more with aficamten than metoprolol (mean difference 2.30 mL/kg/min, p<0.0001).

Next expected readout: December 2026 · NCT07600177 (registry estimate)

Reported efficacy

Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) (Baseline to Week 24): Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) (Baseline to Week 24): Aficamten 1.07 mL/kg/min (Standard Deviation 2.767) | Metoprolol -1.24 mL/kg/min (Standard Deviation 2.186) (met)

Result source: NCT05767346

HRS-1893

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Hypertrophic Cardiomyopathyundisclosed
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07021963 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Hypertrophic Cardiomyopathy

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

HRS-1893: no structured comparison results are available for Hypertrophic Cardiomyopathy.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Aficamten
Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) (Baseline to Week 24): Aficamten 1.07 mL/kg/min (Standard Deviation 2.767) | Metoprolol -1.24 mL/kg/min (Standard Deviation 2.186) NCT05767346 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change From Baseline in pVO2 at Week 24 (Baseline to Week 24): Aficamten up to 20 mg 1.76 mL/kg/min (Standard Error 0.25) | Placebo to Match Aficamten 0.02 mL/kg/min (Standard Error 0.25) NCT05186818 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aficamten's landscape · HRS-1893's landscape